| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Over the last 12 months, insiders at Palisade Bio, Inc. have bought $0 and sold $0 worth of Palisade Bio, Inc. stock.
On average, over the past 5 years, insiders at Palisade Bio, Inc. have bought $61,448 and sold $192 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $4,863 was made by Williams Donald Allen (director) on 2024‑05‑28.
| 2024-05-28 | Williams Donald Allen | director | 1,000 0.1091% | $4.86 | $4,863 | -49.37% | ||
| 2024-05-24 | Finley John David | CEO, CFO, Director | 1,000 0.0994% | $4.81 | $4,810 | -50.71% | ||
| 2024-02-06 | Finley John David | CEO, CFO, Director | 10,000 0.0819% | $0.47 | $4,692 | -43.76% | ||
| 2024-01-31 | Finley John David | CEO, CFO, Director | 10,000 0.0976% | $0.56 | $5,590 | -56.28% | ||
| 2024-01-31 | Williams Donald Allen | director | 10,000 0.1056% | $0.60 | $6,050 | -56.28% | ||
| 2023-09-27 | Finley John David | CEO, CFO, Director | 15,000 0.1655% | $0.54 | $8,088 | -24.34% | ||
| 2023-09-27 | Williams Donald Allen | director | 20,000 0.221% | $0.54 | $10,800 | -24.34% | ||
| 2023-09-14 | Sale | Trenschel Robert J. | director | 300 0.0034% | $0.64 | $192 | -33.15% | |
| 2023-09-13 | Finley John David | CEO, CFO, Director | 15,000 0.2077% | $0.66 | $9,825 | -35.85% | ||
| 2022-09-01 | Finley John David | Chief Financial Officer | 19,481.24 0.0402% | $0.14 | $2,799 | -69.79% | ||
| 2022-08-23 | Finley John David | Chief Financial Officer | 7,350 0.0144% | $0.16 | $1,176 | -73.51% | ||
| 2022-03-29 | Dawson Michael John | Chief Medical Officer | 15,000 0.0958% | $1.14 | $17,093 | -89.84% | ||
| 2022-03-28 | Hallam Thomas | Chief Executive Officer | 10,000 0.0655% | $1.18 | $11,800 | -89.81% | ||
| 2022-03-24 | Finley John David | Chief Financial Officer | 7,500 0.045% | $1.09 | $8,174 | -89.78% | ||
| 2021-09-21 | Finley John David | Chief Financial Officer | 2,000 0.0164% | $2.44 | $4,880 | -62.00% | ||
| 2021-09-21 | Hallam Thomas | Chief Executive Officer | 6,000 0.0502% | $2.49 | $14,940 | -62.00% | ||
| 2021-09-10 | Trenschel Robert J. | director | 2,142 0.0176% | $2.98 | $6,383 | -67.75% | ||
| 2021-09-09 | Trenschel Robert J. | director | 3,400 0.028% | $2.89 | $9,826 | -66.59% | ||
| 2021-09-08 | Trenschel Robert J. | director | 5,000 0.0424% | $2.75 | $13,750 | -63.62% | ||
| 2021-09-07 | Trenschel Robert J. | director | 2,707 0.0215% | $2.78 | $7,525 | -66.09% |
| JOHE KARL | Chief Scientific Officer | 826304 17.2303% | $631,874.67 | 0 | 30 | |
| GARR RICHARD | CEO | 240000 5.0045% | $183,528.00 | 2 | 3 | |
| OLDAKER WILLIAM CLYDE | director | 116939 2.4384% | $89,423.25 | 7 | 0 | |
| CONRON JOHN | Chief Financial Officer | 51364 1.0711% | $39,278.05 | 3 | 0 | |
| Daly Richard J | Chief Executive Officer | 23312 0.4861% | $17,826.69 | 7 | 0 | |
| Hallam Thomas | Chief Executive Officer | 17592 0.3668% | $13,452.60 | 2 | 0 | <0.0001% |
| Dawson Michael John | Chief Medical Officer | 15000 0.3128% | $11,470.50 | 1 | 0 | <0.0001% |
| Finley John David | CEO, CFO, Director | 8437 0.1759% | $6,451.77 | 10 | 0 | <0.0001% |
| LLOYD JONES JONATHAN BRIAN | Chief Financial Officer | 7859 0.1639% | $6,009.78 | 2 | 0 | |
| Williams Donald Allen | director | 1000 0.0209% | $764.70 | 3 | 0 | <0.0001% |
| Trenschel Robert J. | director | 0 0% | $0 | 5 | 1 |
$13,665,147 | 42 | -70.74% | $2.53M | |
$47,363 | 28 | -14.61% | $4.29M | |
$1,138,733 | 28 | -4.94% | $5.09M | |
$193,112 | 22 | -20.59% | $1.44M | |
$742,412 | 14 | -50.36% | $5.14M | |
$139,855 | 11 | -32.84% | $5.16M | |
$4,146,041 | 11 | -40.86% | $1.1M | |
$111,748 | 9 | -47.72% | $5.01M | |
$100,375 | 8 | -51.85% | $3.83M | |
$159,974 | 7 | -18.60% | $4.5M | |
Palisade Bio, Inc. (PALI) | $46,740 | 5 | -73.90% | $3.67M |
$115,514 | 4 | -94.89% | $3.92M | |
$53,042 | 3 | -44.40% | $3.36M | |
$37,465 | 3 | -40.67% | $2.72M | |
$14,530 | 3 | 62.23% | $4.44M | |
$552,301 | 2 | -80.60% | $1.27M | |
$1,049,630 | 1 | -74.91% | $4.65M | |
$739,010 | 1 | 3.33% | $4.11M | |
$37,000 | 1 | 79.42% | $1.01M |
| Increased Positions | 9 | +150% | 131,498 | +66.01% |
| Decreased Positions | 2 | -33.33% | 70,122 | -35.2% |
| New Positions | 4 | New | 47,678 | New |
| Sold Out Positions | <1 | Sold Out | 70,006 | Sold Out |
| Total Postitions | 13 | +116.67% | 260,599 | +30.81% |
| Armistice Capital, Llc | $83.00 | 2.63% | 105,367 | +53,367 | +102.63% | 2024-12-31 |
| Cetera Investment Advisers | $55.00 | 1.75% | 70,006 | +70,006 | New | 2024-12-31 |
| Geode Capital Management, Llc | $8.00 | 0.25% | 10,052 | +10,052 | New | 2024-12-31 |
| Ubs Group Ag | $7.00 | 0.22% | 8,974 | +8,943 | +28,848.39% | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $4.00 | 0.12% | 4,686 | +3,089 | +193.43% | 2024-12-31 |
| Federation Des Caisses Desjardins Du Quebec | $0 | <0.01% | 100 | 0 | 0% | 2024-12-31 |
| Wells Fargo & Company/Mn | $0 | <0.01% | 21 | 0 | 0% | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | 0% | 10 | +<1 | +11.11% | 2024-12-31 |
| Morgan Stanley | $0 | 0% | 7 | -133 | -95% | 2024-12-31 |
| Jpmorgan Chase & Co | $0 | 0% | 0 | -8,200 | Sold Out | 2024-12-31 |